TG Therapeutics Ukoniq’s Future In Doubt Amidst Scrutiny Of P13K Inhibitor Accelerated Approvals

 
• By Bridget Silverman

Advisory committee review of combo with ublituximab may provide forum to discuss the Phase III data showing increased risk of death that prompted US FDA safety alert.

GREEN BLURRY BUBBLES
The risk profile of the leukemia and lymphoma therapies are blurry after FDA's drug safety communication. • Source: Alamy

More from Review Pathways

More from Pathways & Standards